Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients.

Archives of Toxicology
Wei-Ting ChangJhih-Yuan Shih

Abstract

Cancer patients with diabetes have an increasing risk of Dox-induced cardiotoxicity. Despite previous studies reporting benefits of dapagliflozin on the cardiovascular system, it remains unknown whether dapagliflozin has a cardioprotective effect in cancer patients with diabetes. We aimed to investigate the potential of dapagliflozin for preventing doxorubicin (Dox)-induced cardiotoxicity. Using Taiwan National Health Insurance Database, the incidence of heart failure of cancer patients with or without diabetes was investigated. Streptozotocin (STZ)-induced diabetic rats were pretreated with oral dapagliflozin for 6 weeks followed by Dox for 4 weeks via intraperitoneal injection. Sequential echocardiography was applied to assess cardiac function. For in vitro analysis, cardiomyocytes cultured in high glucose were treated with dapagliflozin at 10 μM and subsequently exposed to Dox at 1 μM. Apoptosis and endoplasmic reticulum (ER) stress-related protein expression were measured. Among the studied patients, those with diabetes had a higher risk of major adverse cardiovascular events including the development of heart failure. In diabetic rats, dapagliflozin reduced cardiac fibrosis and significantly improved cardiac function. Dapa...Continue Reading

References

Feb 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L H WexlerM E Horowitz
Jun 4, 2011·Expert Opinion on Drug Safety·Pierantonio MennaGiorgio Minotti
Apr 3, 2012·Journal of Molecular and Cellular Cardiology·Yanti OctaviaAn L Moens
Apr 1, 2009·Journal of Clinical Medicine Research·Douraid K Shakir, Kakil I Rasul
Jul 5, 2012·Current Cardiology Reviews·Maria Volkova, Raymond Russell
Mar 16, 2013·Medicinal Research Reviews·Filipa S CarvalhoPaulo J Oliveira
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Feb 4, 2016·Circulation Research·Hai Ying FuTetsuo Minamino
Apr 27, 2017·Oncotarget·Navid Koleini, Elissavet Kardami
Jul 12, 2017·Asia-Pacific Journal of Oncology Nursing·Denise Soltow Hershey, Sarah Hession
Oct 1, 2017·Experimental and Therapeutic Medicine·Fan XuQingshan Li
Jul 12, 2018·Cardiovascular Diabetology·Sarayut LahnwongNipon Chattipakorn
May 24, 2019·Clinical Epidemiology·Cheng-Yang HsiehEdward Chia-Cheng Lai
Aug 23, 2019·European Heart Journal·Marcelo B BastosNicolas M Van Mieghem
Sep 20, 2019·The New England Journal of Medicine·John J V McMurrayUNKNOWN DAPA-HF Trial Committees and Investigators

❮ Previous
Next ❯

Citations

Jun 6, 2021·Cardiovascular Toxicology·Veysel Özgür BarışAyşen Erdem

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
Protein Assay

Software Mentioned

STATA
SAS

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.